DrugPatentWatch Database Preview
TYBOST Drug Profile
see a sample report or, see our see our flat-rate plans
When do Tybost patents expire, and when can generic versions of Tybost launch?
This drug has one hundred and sixty-one patent family members in thirty-one countries.
The generic ingredient in TYBOST is cobicistat. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cobicistat profile page.
Summary for TYBOST
| International Patents: | 161 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 41 |
| Clinical Trials: | 2 |
| Patent Applications: | 45 |
| Formulation / Manufacturing: | see details |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for TYBOST |
| DailyMed Link: | TYBOST at DailyMed |
Pharmacology for TYBOST
Medical Subject Heading (MeSH) Categories for TYBOST
Synonyms for TYBOST
| 1,3-thiazol-5-ylmethyl [(2R,5R)-5-{[(2S)-2-({[(2-isopropyl-1,3-thiazol-4-yl)methyl](methyl)carbamoyl}amino)-4-(morpholin-4-yl)butanoyl]amino}-1,6-diphenylhexan-2-yl]carbamate |
| 1,3-thiazol-5-ylmethyl N-[(2R,5R)-5-[[(2S)-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]-4-morpholin-4-ylbutanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate |
| 1004316-88-4 |
| 2,7,10,12-Tetraazatridecanoic acid, 12-methyl-13-(2-(1-methylethyl)-4-thiazolyl)-9-(2-(4-morpholinyl)ethyl)-8,11-dioxo-3,6-bis(phenylmethyl)-, 5-thiazolylmethyl ester, (3R,6R,9S)- |
| AB0093115 |
| AB01566899_01 |
| AK174896 |
| AKOS025404908 |
| AOB87771 |
| AS-17061 |
| BDBM50447471 |
| CHEBI:72291 |
| CHEMBL2095208 |
| Cobicistat |
| Cobicistat (GS-9350) |
| Cobicistat (JAN/USAN/INN) |
| Cobicistat [USAN:INN] |
| Cobicistat,GS-9350 |
| Cobicistat/darunavir |
| cobicistatum |
| CS-0742 |
| D02VJP |
| D09881 |
| D0V4ZN |
| DB09065 |
| DTXSID00143269 |
| GS 9350 |
| GS-9350 |
| GTPL7535 |
| HY-10493 |
| KB-76152 |
| KS-00000T52 |
| LW2E03M5PG |
| MFCD18251449 |
| MolPort-035-395-741 |
| QCR-199 |
| s2900 |
| SCHEMBL2736227 |
| Thiazol-5-ylmethyl ((1R,4R)-1-benzyl-4-({(2S)-2-((methyl{(2-(1-methylethyl)thiazol-4-yl)methyl}carbamoyl)amino)-4-(morpholin-4-yl)butanoyl}amino)-5-phenylpentyl)carbamate |
| thiazol-5-ylmethyl ((2R,5R)-5-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-4-morpholinobutanamido)-1,6-diphenylhexan-2-yl)carbamate |
| thiazol-5-ylmethyl (2R,5R)-5-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-4-morpholinobutanamido)-1,6-diphenylhexan-2-ylcarbamate |
| thiazol-5-ylmethyl N-[(1R,4R)-1-benzyl-4-[[(2S)-2-[[(2-isopropylthiazol-4-yl)methyl-methyl-carbamoyl]amino]-4-morpholino-butanoyl]amino]-5-phenyl-pentyl]carbamate |
| Tybost (TN) |
| UNII-LW2E03M5PG |
| ZCIGNRJZKPOIKD-CQXVEOKZSA-N |
| ZINC85537014 |
US Patents and Regulatory Information for TYBOST
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences Inc | TYBOST | cobicistat | TABLET;ORAL | 203094-001 | Sep 24, 2014 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
Paragraph IV (Patent) Challenges for TYBOST
| Drugname | Dosage | Strength | RLD | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 150 mg | ➤ Subscribe | 2015-12-09 |
Non-Orange Book US Patents for TYBOST
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 8,383,655 | Modulators of pharmacokinetic properties of therapeutics | ➤ Sign Up |
| 9,139,541 | Modulators of pharmacokinetic properties of therapeutics | ➤ Sign Up |
| 7,939,553 | Modulators of pharmacokinetic properties of therapeutics | ➤ Sign Up |
| 8,486,942 | Modulators of pharmacokinetic properties of therapeutics | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
see a sample report or, see our see our flat-rate plans
International Patents for TYBOST
Supplementary Protection Certificates for TYBOST
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| /2015 | Austria | ➤ Sign Up | PRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/13/830 (MITTEILUNG) 20130527 |
| 2016040 | Lithuania | ➤ Sign Up | PRODUCT NAME: DARUNAVIRAS + KOBICISTATAS; REGISTRATION NO/DATE: EU/1/14/967 20141119 |
| 2017 00002 | Denmark | ➤ Sign Up | PRODUCT NAME: COBICISTAT ELLER ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF OG DARUNAVIR ELLER ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF, ISAER DARUNAVIRETHANOLAT; REG. NO/DATE: EU/1/14/967/001 20141121 |
| /2016 | Austria | ➤ Sign Up | PRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ ODER SOLVAT DAVON UND DARUNAVIR ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ ODER SOLVAT DAVON, INSVBESONDERE DARUNAVIR-ETHANOLAT; REGISTRATION NO/DATE: EU/1/14/967 (MITTEILUNG) 20141121 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
